Celgene (BUE:CELG) Beneish M-Score: -2.53 (As of Jul. 08, 2026)

What is Celgene Beneish M-Score?

Celgene BUE:CELG 10 Beneish M-Score is -2.53 as of Jul. 08, 2026. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Celgene's Beneish M-Score or its related term are showing as below:

BUE:CELG' s Beneish M-Score Range Over the Past 10 Years
Min: -10000000 Med: -2.29 Max: 10000000
Current: -2.53

During the past 13 years, the highest Beneish M-Score of Celgene was 10000000.00. The lowest was -10000000.00. And the median was -2.29.

Celgene Beneish M-Score Related Terms

Celgene Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Celgene's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene Beneish M-Score Chart

Celgene Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Beneish M-Score

Get a 7-Day Free Trial

-2.58

-2.29

-2.67

-2.96

-2.39

Celgene Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Beneish M-Score	Get a 7-Day Free Trial															-2.74	-2.39	-2.55	-2.54	-2.53

BUE:CELG vs GILD, BIIB, ACT: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Celgene's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celgene Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celgene's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Celgene's Beneish M-Score falls into.

Save Embed

Celgene Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Celgene for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 0.8435

0.528 * 0.9998

0.404 * 0.841

0.892 * 2.0177

0.115 * 0.8891

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.8831

4.679 * -0.027376

0.327 * 0.8227

-1.84

This Year (Sep19) TTM:

Last Year (Sep18) TTM:

Total Receivables was ARS132,768.32 Mil.
Revenue was 252785.516 + 196587.605 + 157337.25 + 152215.093 = ARS758,925.46 Mil.
Gross Profit was 243445.874 + 189841.075 + 151864.65 + 145842.948 = ARS730,994.55 Mil.
Total Current Assets was ARS808,354.39 Mil.
Total Assets was ARS2,313,267.10 Mil.
Property, Plant and Equipment(Net PPE) was ARS79,135.29 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS29,169.61 Mil.
Selling, General, & Admin. Expense(SGA) was ARS141,374.48 Mil.
Total Current Liabilities was ARS280,133.33 Mil.
Long-Term Debt & Capital Lease Obligation was ARS1,022,830.60 Mil.
Net Income was 94570.865 + 70190.711 + 60394.05 + 40457.467 = ARS265,613.09 Mil.
Non Operating Income was -13086.684 + -12152.688 + 7231.65 + -17382.006 = ARS-35,389.73 Mil.
Cash Flow from Operations was 121471.27 + 96819.395 + 57696.84 + 88342.82 = ARS364,330.33 Mil.

Total Receivables was ARS78,013.88 Mil.
Revenue was 143221.708 + 95121.164 + 71287.162 + 66507.882 = ARS376,137.92 Mil.
Gross Profit was 137444.265 + 91978.724 + 68567.047 + 64235.577 = ARS362,225.61 Mil.
Total Current Assets was ARS288,025.77 Mil.
Total Assets was ARS1,259,077.78 Mil.
Property, Plant and Equipment(Net PPE) was ARS48,317.09 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS15,212.63 Mil.
Selling, General, & Admin. Expense(SGA) was ARS79,342.92 Mil.
Total Current Liabilities was ARS135,530.72 Mil.
Long-Term Debt & Capital Lease Obligation was ARS726,485.86 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(132768.322 / 758925.464)	/	(78013.88 / 376137.916)
	=	0.174943	/	0.207408
	=	0.8435

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(362225.613 / 376137.916)	/	(730994.547 / 758925.464)
	=	0.963013	/	0.963197
	=	0.9998

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (808354.391 + 79135.289) / 2313267.102)	/	(1 - (288025.773 + 48317.087) / 1259077.784)
	=	0.616348	/	0.732866
	=	0.841

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	758925.464	/	376137.916
	=	2.0177

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(15212.625 / (15212.625 + 48317.087))	/	(29169.608 / (29169.608 + 79135.289))
	=	0.239457	/	0.269329
	=	0.8891

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(141374.475 / 758925.464)	/	(79342.92 / 376137.916)
	=	0.186282	/	0.210941
	=	0.8831

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((1022830.598 + 280133.33) / 2313267.102)	/	((726485.858 + 135530.717) / 1259077.784)
	=	0.563257	/	0.684641
	=	0.8227

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(265613.093 - -35389.728	-	364330.325)	/	2313267.102
	=	-0.027376

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Celgene has a M-score of -1.84 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -2.53 mean?

Celgene (BUE:CELG) has a Beneish M-Score of -2.53 as of Jul. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Celgene and its competitors.

Is Celgene's Beneish M-Score too high?

Celgene's current Beneish M-Score is -2.53. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Celgene's Beneish M-Score compare to GILD and BIIB?

Celgene's Beneish M-Score of -2.53 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Drug Manufacturers company?

A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Celgene and its competitors. Celgene's current Beneish M-Score is -2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Celgene stock overvalued right now?

Celgene (BUE:CELG) has a current Beneish M-Score of -2.53. The current Beneish M-Score is -2.53. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Celgene (BUE:CELG), the current Beneish M-Score is -2.53 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XTER:BAYA GILD TSE:4519 BIIB SHSE:600276 LSE:GSK TSE:4568 ACT TSE:4503 XPAR:SAN LSE:AZN AMGN XMAD:GRF TSE:4578 LLY HKSE:01093 ABBV TSE:4151 TSE:4528 SHSE:600436

Address 86 Morris Avenue, Summit, NJ, USA, 07901

Website http://www.celgene.com

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.